Compare · PCRX vs SCLX
PCRX vs SCLX
Side-by-side comparison of Pacira BioSciences Inc. (PCRX) and Scilex Holding Company (SCLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. PCRX focuses on Biotechnology: Pharmaceutical Preparations, while SCLX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- PCRX is the larger of the two at $1.46B, about 120.4x SCLX ($12.1M).
- PCRX has hit the wire 10 times in the past 4 weeks while SCLX has been quiet.
- PCRX has more recent analyst coverage (25 ratings vs 6 for SCLX).
- Company
- Pacira BioSciences Inc.
- Scilex Holding Company
- Price
- -
- -
- Market cap
- $1.46B
- $12.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2011
- 2021
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 6
Pacira BioSciences Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.
Latest PCRX
- Pacira BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Amendment: SEC Form SC 14D9/A filed by Pacira BioSciences Inc.
- Ingram Micro Holding Set to Join S&P SmallCap 600
- SEC Form 10-Q filed by Pacira BioSciences Inc.
- Pacira BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Viatris Reports Third-Quarter 2026 Financial Results
- Chief Financial Officer Cross Shawn covered exercise/tax liability with 9,540 shares, decreasing direct ownership by 9% to 95,801 units (SEC Form 4) (tax liability)
- Amendment: SEC Form SC 14D9/A filed by Pacira BioSciences Inc.
- Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
- SEC Form SC 14D9 filed by Pacira BioSciences Inc.
Latest SCLX
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13D/A filed by Scilex Holding Company
- Large owner Scilex Holding Co disposed of $15,755,000 worth of shares (50,000,000 units at $0.32), decreasing direct ownership by 23% to 163,766,229 units (SEC Form 4)
- SEC Form 10-Q filed by Scilex Holding Company
- JP 3E Holdings, Inc. Appoints Henry Ji, Ph.D., Stephen Ma and Jaedong Yoon to Board of Directors
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Large owner Sclx Stock Acquisition Jv Llc disposed of 500,000 shares, decreasing direct ownership by 34% to 958,263 units (SEC Form 4)
- Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026